Hello JITC Readers,
For many of us, this edition of the digest coincides with the
beginning of the academic year. As we look ahead, you can also take
some time to reacquaint yourself with papers from the JITC archive in this month’s special feature. If you are seeking more contemporary recommendations, be sure to browse the monthly JITC's Reading List for
selections by our editors of exciting research from other journals. Our
colleagues in academia might find these resources useful to round out
the reading lists in their syllabi.
Even if you left the classroom long ago, there is always more
to learn in the immunotherapy field. The papers selected for this
month’s digest emphasize how new insights may be found in familiar
pathways or strategies as our field continues to advance.
Two papers provide surprising insights into mechanisms of
anti-tumor efficacy for familiar families of agents. Casey R Ager and
colleagues reveal several novel mechanisms of myeloid reprogramming
induced by cyclic dinucleotides, revealing STING signaling as a
potential target to potentiate checkpoint blockade in immunologically
cold tumors. Pu Sun et al show that PI3K inhibitors modulate T
cell metabolism as well as suppressive myeloid cells in the tumor
microenvironment, identifying unappreciated immune mechanisms of action.
Another strategy to target myeloid suppressive cells is
described by David G DeNardo and colleagues, who explain the preclinical
rationale and study design for an ongoing phase I/II trial of a
first-in-class CD11b modulator for solid tumors.
Finally, Michael J Wagner et al provide the first
prospective trial data for combination ipilimumab and nivolumab
immunotherapy for the rare tumor angiosarcoma.
Whether you are an early-career trainee or an emeritus, or at any other stage, I wish everyone a safe and smooth September.
Best,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer
To view the entire April 2021 JITC Digest, please click here.
